ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

mezigdomide

Also written as “CC-92480”, “Mezigdomide” and “Cohort B1 & B2: KTX-1001+Mezigdomide”.

Its studies are mostly in Multiple Myeloma · Kidney Failure, Chronic, led by 2 companies.

Drug pageMezigdomide: every studyAll 22 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Aug 25, 202212 company-led studies, 4 open or runningNext primary completion: Jan 10, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibbits history only113 open or runningphase 3since Aug 25, 2022Dec 1, 2017Jan 10, 2027phase 3 · NCT05519085
K36 Therapeutics11 open or runningphase 1since Dec 1, 2022Dec 1, 2022Dec 31, 2027phase 1 · NCT05651932
  • Named in Bristol-Myers Squibb’s own pipeline as mezigdomide, phase 4, as of Oct 29, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of K36 Therapeutics only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jul 28, 2021Named mezigdomideINNProposed as its International Nonproprietary Name in WHO's List 125 · before, CC-92480
  2. Dec 1, 2022First study: phase 1 study in Multiple MyelomaFirst studyNCT05651932 · 165 planned · United States, Canada, France and more

Ahead

  1. Dec 31, 2027Primary completion: phase 1 study in Multiple MyelomaNCT05651932

TargetBeta

“A modulator of the E3 ubiquitin ligase complex containing cereblon (CRL4-CRBN E3 ubiquitin ligase), with potential immunomodulating and antineoplastic activities. Upon administration, mezigdomide specifically binds to cereblon (CRBN), thereby affecting the ubiquitin E3 ligase activity, and target…”NCIt, read by Claude

Other programs on CRBN

ProgramCompanyFurthest phaseStudies
LenalidomideruleBristol-Myers Squibbphase 4109
pomalidomideruleBristol-Myers Squibbphase 451
golcadomideBristol-Myers Squibbphase 311
Cereblon E3 Ubiquitin Ligase Modulating Drug BMS-986506Bristol-Myers Squibbphase 11
HRS-3738Jiangsu HengRui Medicinephase 11

Studies

The one study K36 Therapeutics leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05651932Multiple Myeloma · United States, Canada, France and more1RecruitingDec 31, 2027165

How it is read

Names in the registry

  • “CC-92480”, 6 entries
  • “Mezigdomide”, 4 entries
  • “Cohort B1 & B2: KTX-1001+Mezigdomide”, 1 entry
  • “mezigdomide”, 1 entry
  • “[14C]-CC-92480”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.